Real-world resource use and costs of adjuvant treatment for stage III colon cancer
In: European Journal of Cancer Care, Jg. 24 (2013-12-25), S. 321-332
Online
unknown
Zugriff:
Since the generalisability of trial-based economic evaluations may be limited, there is an increasing focus on real-world cost-effectiveness. Real-world studies involve evaluating the effects and costs of treatments in daily clinical practice. This study reports on the real-world resource use and costs of adjuvant treatments of stage III colon cancer in a population-based observational study. Analyses were based on a detailed retrospective medical chart review which was conducted for 206 patients with colon cancer treated in 2005 and 2006 in the Netherlands. Mean total costs per patient were €9681 for 5-FU/LV, €9736 for capecitabine, €32,793 for FOLFOX and €18,361 for CAPOX. Drug costs and the costs related to hospitalisations for chemotherapy administration were the main cost drivers. We identified a potential for substantial cost-savings when the 48 h administration of 5FU/LV in the FOLFOX regimen were to take place in an outpatient setting or be replaced by oral capecitabine as in the CAPOX regimen. This analysis based on detailed real-life data clearly indicates that clinical choices made in oncology based on efficacy of therapy have economic consequences. Considering today's reality of finite healthcare resources, these economic consequences deserve a formal role in clinical decision making, for instance in guideline development.
Titel: |
Real-world resource use and costs of adjuvant treatment for stage III colon cancer
|
---|---|
Autor/in / Beteiligte Person: | S. de Groot ; Siok Swan Tan ; C. W. M. van Gils ; Redekop, William K. ; C.A. Uyl-de Groot ; Punt, C.J.A. ; Koopman, Miriam |
Link: | |
Zeitschrift: | European Journal of Cancer Care, Jg. 24 (2013-12-25), S. 321-332 |
Veröffentlichung: | Hindawi Limited, 2013 |
Medientyp: | unknown |
ISSN: | 0961-5423 (print) |
DOI: | 10.1111/ecc.12154 |
Schlagwort: |
|
Sonstiges: |
|